Learning Objectives:

Upon completion of this activity, clinicians should be able to:

• Discuss the mechanisms of action of inhibitors of immunoregulatory T-cells, as well as advances in understanding the molecular biology and genetics of malignant melanoma.
  
  
• Apply the management of immuno-related adverse effects (IRAEs) and the need to customize treatment for the individual patient.
  
  
• Describe recent clinical trials involving novel biologic agents for the treatment of malignant melanoma with emphasis on efficacy and safety.